Dalpiciclib plus hormone therapy for early hormone-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older with early-stage (stage II or III) breast cancer
- Your cancer is hormone-receptor positive (ER or PR ≥10%) and HER2-negative
- You had surgery within the last 12 months, with good recovery from any chemotherapy or radiation
- Your blood counts and organ function (liver, kidney, heart) are adequate for the study
- You are not pregnant, do not have HIV or other immune system diseases, and have no serious heart conditions
- You are not currently enrolled in another cancer clinical trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (dalpiciclib) combined with hormone therapy for women with early-stage, hormone receptor positive/HER2-negative breast cancer. The goal is to see if this combination can lower the chance of cancer coming back after surgery.
This trial tests a new combination of oral hormone therapy (an aromatase inhibitor) plus a CDK4/6 inhibitor (dalpiciclib) for women with early-stage but locally advanced (Stage II–III) hormone receptor-positive, HER2-negative breast cancer. The goal is to shrink the tumor before surgery, potentially improving outcomes.
This trial tests a pill called Dalpiciclib given after surgery to help prevent early-stage breast cancer from coming back. It is for women with hormone receptor-positive (HR+) and HER2-negative breast cancer that has not spread to other parts of the body.
This trial tests dalpiciclib together with hormone (endocrine) therapy in people with HR-positive, HER2-negative advanced breast cancer whose cancer has already responded poorly to a prior CDK4/6 inhibitor. It aims to see if this combination can better control the cancer after that earlier treatment has failed.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
Hear when a new Breast Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.